Prediction of trifluridine/tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer (mCRC): Real-life data from the Czech Republic.

被引：0
|
作者：
Grell, Peter
Dvorak, Josef
Vocka, Michal
John, Stanislav
Tuskova, Helena
Buchler, Tomas
Borilova, Simona
Selingerova, Iveta
Vyzula, Rostislav
Petruzelka, Lubos B.
Kiss, Igor
Obermannova, Radka
机构：
[1] Masaryk Mem Canc Inst, Brno, Czech Republic
[2] Charles Univ Med Sch & Teaching Hosp, Hradec Kralove, Czech Republic
[3] Charles Univ Prague, Prague, Czech Republic
[4] Dept Oncol & Radiotherapy, Hradec Kralove, Czech Republic
[5] Charles Univ Prague, Fac Med 1, Dept Oncol, Prague, Czech Republic
[6] Thomayer Univ Hosp, Prague, Czech Republic
[7] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, Brno, Czech Republic
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e15102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15102
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)
    Qvortrup, C.
    Yilmaz, M.
    Moller, S.
    Zitnjak, D.
    Maltha, L.
    Krogh, M.
    Petersen, L. Noergaard
    Hejlesen, F.
    Winther, S. B.
    Thomsen, K. G.
    Pfeiffer, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
    Cecchini, Michael
    Kortmansky, Jeremy S.
    Lacy, Jill
    Fischbach, Neal A.
    Thumar, Jaykumar Ranchodbhai
    Sabbath, Kert D.
    Gomez, Christina M.
    Sporn, Jonathan
    Stein, Stacey
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [33] A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC).
    Patel, Manish R.
    Bendell, Johanna C.
    Mayer, Robert J.
    Benedetti, Fabio M.
    Rosen, Lee S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : E181 - E182
  • [35] Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme
    Sforza, Vincenzo
    Martinelli, Erika
    Cardone, Claudia
    Martini, Giulia
    Napolitano, Stefania
    Vitiello, Pietro Paolo
    Vitale, Pasquale
    Zanaletti, Nicoletta
    Reginelli, Alfonso
    Di Bisceglie, Maurizio
    Latiano, Tiziana Pia
    Bochicchio, Anna Maria
    Cecere, Fabiana
    Selvaggi, Francesco
    Ciardiello, Fortunato
    Troiani, Teresa
    ESMO OPEN, 2017, 2 (04)
  • [36] Safety and efficacy on TAS-102 monotherapy in clinical practice in patients with metastatic colorectal cancer (mCRC)
    Kotani, Daisuke
    Shitara, Kohei
    Fukuoka, Shota
    Bando, Hideaki
    Okamoto, Wataru
    Kojima, Takashi
    Doi, Toshihiko
    Yoshino, Takayuki
    ANNALS OF ONCOLOGY, 2015, 26 : 72 - 72
  • [37] The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
    Van Cutsem, Eric
    Mayer, Robert J.
    Laurent, Stephanie
    Winkler, Robert
    Gravalos, Cristina
    Benavides, Manuel
    Longo-Munoz, Federico
    Portales, Fabienne
    Ciardiello, Fortunato
    Siena, Salvatore
    Yamaguchi, Kensei
    Muro, Kei
    Denda, Tadamichi
    Tsuji, Yasushi
    Makris, Lukas
    Loehrer, Patrick
    Lenz, Heinz-Josef
    Ohtsu, Atsushi
    EUROPEAN JOURNAL OF CANCER, 2018, 90 : 63 - 72
  • [38] Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center
    Sales, C.
    Juliao, I.
    Rosinha, A.
    Marques, D.
    Carneiro, F.
    Faustino, C.
    Machado, M.
    Ferreira, P.
    Fragoso, M.
    Sousa, N.
    ANNALS OF ONCOLOGY, 2018, 29 : 79 - 79
  • [39] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 925 - 932
  • [40] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Bendell, Johanna C.
    Rosen, Lee S.
    Mayer, Robert J.
    Goldman, Jonathan W.
    Infante, Jeffrey R.
    Benedetti, Fabio
    Lin, Donghu
    Mizuguchi, Hirokazu
    Zergebel, Christopher
    Patel, Manish R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 925 - 932
12345